Addressing one of biggest remaining challenges in calcium modification today, NODULE-SHOCK adds a significant chapter in the nodular evidence compendium with excellent outcomes in both arms, as well as represents the first peer-reviewed, published data highlighting the benefits of the more deliverable #ShockwaveC2Aero#, which was associated with a low use of guide extension support (9%) in the calcified nodule arm. Thank you, Dr. @DoctorKini for presenting this important investigator-led research at #TCT2026#. Johnson & Johnson MedTech is committed to supporting research like NODULE-SHOCK that improves our understanding of the role of #ShockwaveIVL# in your treatment algorithm in even the most difficult-to-treat lesions. Learn more in @JACCJournals: US Rx only. Safety info: Product availability may vary by country.